Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: According ...

Mylan is releasing a generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew scorn from parents nationwide and spawned Congressional ...

Drugmaker Mylan has started selling a generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew national scorn and attracted ...

(Reuters) - Mylan NV, which has come under fire for its drug pricing, said on Friday it would start selling a generic version of its life-saving EpiPen allergy treatment for $300 per two-pack, a more ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Updated at 12:40 p.m. WASHINGTON • U.S. Sens. Richard Blumenthal, Charles Grassley and Amy Klobuchar asked the Justice Department ...

Mylan will start selling a cheaper version of its EpiPen after absorbing waves of criticism over a list price for the emergency allergy treatment that has grown to $608 for a two-pack, making it ...

CVS Health Corp (ticker: CVS) is gearing up for a fight with Mylan NV (MYL) on drug pricing, offering a cheaper generic option of Mylan’s EpiPen that’s nearly one-sixth the cost. This follows intense ...

Mylan NV said on Thursday, Aug. 25, it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount program, a day after Democratic Presidential candidate Hillary ...

(Reuters) - Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar to Amgen Inc's blockbuster drug, Neulasta, to market, with U.S. health regulators approving its version of the ...

WASHINGTON (Reuters) – Democrat Elizabeth Warren and 19 other U.S. senators voiced concern to the chief executive of Mylan NV about the high cost of its EpiPen on Tuesday, calling the device used in ...

Clears way for shareholder meeting on whether Southpointe generic pharmaceutical giant will proceed with takeover of Perrigo. Teva Pharmaceutical Industries on Monday ended its hostile bid for Mylan ...

Heather Bresch will face the proverbial lash from Congress on Wednesday over the escalating cost of Mylan NV’s EpiPen. Her boss won’t. Robert J. Coury acquired the rights to sell the emergency allergy ...